Epilogen
Immuno-oncology company developing novel cancer immunotherapies using the IgE class of antibodies, which may offer advantages over traditional IgG antibodies in tumor targeting.
Notes
Epilogen is an immuno-oncology company developing cancer immunotherapies using the IgE class of antibodies. While most therapeutic antibodies are of the IgG class, IgE antibodies have unique properties that may offer advantages in cancer treatment.
IgE antibodies trigger potent immune responses and have evolved to provide rapid, localized defense against pathogens and parasites. In cancer, IgE antibodies may enhance tumor cell killing through more effective activation of immune effector cells and potentially overcome some resistance mechanisms seen with IgG-based therapies.
This represents an innovative approach to cancer immunotherapy that is being explored by a small number of companies worldwide.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Focus on IgE-based cancer immunotherapy
- Novel antibody class for oncology
- Immuno-oncology approach
- Differentiated mechanism from IgG antibodies
- Early-stage development
Sources
- Company information pending further verification
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| AlbionVC (Healthcare) | London, UK | biotech-focused | seedseries-a+1 | 17 |